Pharmaceutical services company Quintiles has bolstered its contract research capabilities with the acquisition of Novella Clinical for an undisclosed amount.
The US-headquartered contract research organisation (CRO) has more than 800 employees across North America and Europe and focuses on oncology, medical devices and diagnostics sectors
Quintiles, which said the deal would help it stay ahead of the diverse and evolving needs of its global customer base, also expects a boost for its small biopharma capabilities.
Paula Brown Stafford, president, clinical development at Quintiles, said: “The expertise and insight the Novella team brings will be a strong addition to our existing capabilities and help further differentiate Quintiles in an increasingly competitive marketplace.
“Novella’s understanding of emerging companies, as well as our shared commitment to quality, customer service, and above all, the patients we ultimately serve, makes this acquisition a good fit for both organisations.”
Founded 15 years ago, Novella is a full-service CRO whose offerings include clinical monitoring, data management, regulatory affairs, qualify assurance and safety management.
Once the acquisition is completed Novella will operate as a standalone unit within Quintiles under its existing name.